Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study.

作者信息

Naber Christoph K, Pyxaras Stylianos A, Nef Holger, IJsselmuiden Alexander J, Briguori Carlo, Schlundt Christian, Wykrzykowska Joanna, Eberli Franz R, Möllmann Helge, Galatius Søren, Rieber Johannes, Commeau Philippe, van Geuns Robert-Jan, Bouchez David, Mudra Harald

机构信息

Contilia Heart and Vascular Center, Elisabeth-Krankenhaus, Essen, Germany.

出版信息

EuroIntervention. 2016 Jun 20;12(3):356-8. doi: 10.4244/EIJY15M06_02.

AIMS

We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice.

METHODS AND RESULTS

The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%).

CONCLUSIONS

The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.